ArticleCancer chemotherapy and pharmacology2024

A first-in-human phase I study of TAS-117, an allosteric AKT inhibitor, in patients with advanced solid tumors.

Toshihiko Doi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.